Clinical trials: Metastatic Colorectal Cancer (MCRC)
Colorectal Cancer
Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC
This study is try to evaluate the effect of cetuximab monotherapy as maintenance treatment, versus continuation after 8 courses of induction therapy with cetuximab plus standard chemotherapy regimen (FOLFIRI or mFOLFOX6）in…
- Trial name
- NCT02942706
- Testing
- Cetuximab, mFOLFOX6, FOLFIRI
- Volunteers
- 200 people
- Sponsor
- Ruijin Hospital
Unresectable Metastatic Colorectal Carcinoma
A Phase II Prospective Trial of mXELOXIRI Reintroduction for mCRC
The objective is to evaluate the efficacy and safety of reintroduction of modified XELOXIRI combined with molecular targeted drug in patients with metastatic colorectal cancer (mCRC)
- Trial name
- NCT04508452
- Testing
- Capecitabine-Oxaliplatin-Irinotecan-Bevacizumab Combination
- Where
- China
- Volunteers
- 91 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Metastatic Colorectal Cancer
Soluble Vascular Endothelial Growth Factor Receptor 2 as Predictor of Benefit From Bevacizumab Beyond Progression in Metastatic Colorectal Cancer
A growing amount of reports has consistently evidenced that a sustained inhibition of the angiogenesis is an effective therapeutic strategy, able to improve the outcome of metastatic colorectal cancer (mCRC) patients.
- Trial name
- CIRCUS (NCT02623621)
- Testing
- chemotherapy plus bevacizumab
- Where
- Italy
- Volunteers
- 103 people
- Sponsor
- Azienda Ospedaliero, Universitaria Pisana
Locally Advanced or Metastatic CRC
Phase II Clinical Study of LTC004 in Patients With mCRC
This is a phase II clinical study to evaluate the safety and antitumor activity of LTC004 in patients with locally advanced or metastatic CRC，Enrollment of 10 evaluable subjects in Phase I.
- Trial name
- NCT06384235
- Testing
- LTC004
- Volunteers
- 30 people
- Sponsor
- Letolab
HCC - Hepatocellular Carcinoma, Colorectal Cancer Metastatic
ctDNA Monitoring in Patients With HCC and mCRC
"Liquid biopsy" is a collective term that refers to the analysis of cancer-derived biomarkers isolated from the biological fluids of cancer patients.
- Trial name
- NCT07001085
- Testing
- Tumor Tissue Collection and NGS, Blood Collection for Plasma ctDNA, ctDNA Mutation Analysis via ddPCR
- Where
- Poland
- Volunteers
- 300 people
- Sponsor
- Medical University of Warsaw
Colorectal Cancer Metastatic
Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC
This study is a single-center, prospective, single-arm exploratory study aimed at evaluating the efficacy and safety of trifluridine/tipiracil in combination with cetuximab in the treatment of third-line and above RAS/BRAF…
- Trial name
- NCT06379399
- Testing
- Cetuximab, Trifluridine/Tipiracil
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Wangxia LV
Liver Metastases, Colorectal Cancer
Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC
The purpose of this study is to assess feasibility of chemoembolization with DC Bead loaded with Irinotecan in combination with Cetuximab and 5FU/LV as a first line treatment for wildtype KRAS unresectable liver metastases from…
- Trial name
- NCT01631539
- Testing
- DC Bead™, Cetuximab, 5 FU
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Colorectal Cancer, Drug Resistance
The Emergence of RAS Mutations in Metastatic Colorectal Cancer Patients Receiving Cetuximab Treatment
To evaluate the emergence of RAS mutation in patients with metastatic colorectal cancer, circulating free DNA will be analyzed using mass spectrometric genotyping in subjects during cetuximab treatment.
- Conditions
- Colorectal Cancer, Drug Resistance, Mass Spectrometry, RAS-RAF Pathway Deregulation
- Trial name
- NCT03401957
- Testing
- Cetuximab, liquid biopsy
- Where
- 4 sites in Taiwan
- Volunteers
- 120 people
- Sponsor
- National Health Research Institutes, Taiwan
Metastatic Colorectal Cancer
FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC
Once randomisation has been completed, the study treatment should be started preferably immediately; at the latest within one week following randomisation.
- Trial name
- AIO-KRK-0116 (NCT04034459)
- Testing
- Bevacizumab, Irinotecan, Folinic acid
- Where
- Germany
- Volunteers
- 109 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Colon Cancer, Colorectal Cancer
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
The primary objective of this study is to estimate the treatment effect on progression-free survival (PFS) of panitumumab relative to bevacizumab in combination with mFOLFOX6 chemotherapy as first-line therapy in patients with…
- Conditions
- Colon Cancer, Colorectal Cancer, Rectal Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT00819780
- Testing
- Panitumumab, Bevacizumab, mFOLFOX6
- Where
- 95 sites in United States, Belgium and 4 more
- Volunteers
- 285 people
- Sponsor
- Amgen
Colorectal Cancer Metastatic
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
Primary Objective: To provide metastatic colorectal cancer participants with access to aflibercept and to document the overall safety in these participants Secondary Objective: To document the Health-Related Quality of Life of…
- Trial name
- NCT01571284
- Testing
- AFLIBERCEPT AVE0005, FOLFIRI
- Where
- 179 sites in United States, Belgium and 21 more
- Volunteers
- 781 people
- Sponsor
- Sanofi
Metastatic Colorectal Cancer
Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
The goal of this single-arm study is to evaluate the efficacy and safety of Envafolimab combined with Trifluridine/Tipiracil and Bevacizumab in the treatment of metastatic colorectal cancer patients who are refractory or…
- Trial name
- NCT06060704
- Testing
- Envafolimab, Trifluridine/Tipiracil, Bevacizumab
- Where
- China
- Volunteers
- 33 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Colorectal Cancer Metastatic
Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC
Patient with multiple metastases, not eligible for surgery, might not profit from intensive chemotherapy regimens. Therefore less intensive regimens focusing on survival and disease control may be a better choice for first line…
- Trial name
- NCT01249638
- Testing
- Capecitabine, Bevacizumab, Irinotecan
- Where
- Germany
- Volunteers
- 516 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Colorectal Cancer Metastatic
A Phase lb/ll, Open Label, Single Arm Study With Olinvacimab and Capecitabine in mCRC Patients (OLCAP)
The aim on this study is to assess the safety and efficacy of the anti-VEGFR2 monoclonal antibody olinvacimab and the capecitabine in patients with metastatic colorectal carcinoma who failed two prior chemotherapies
- Trial name
- NCT04751955
- Testing
- Olinvacimab added to Capecitabine
- Sponsor
- Korean Cancer Study Group
Advanced Solid Tumor, Metastatic Colorectal Carcinoma
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
This is a first-in-human, Phase 1, non-randomized, multicenter, open-label clinical study designed to investigate the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics (PK) of [225Ac]-FPI-2068…
- Conditions
- Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT06147037
- Testing
- FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068
- Where
- 8 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- AstraZeneca
Metastatic Colorectal Cancer
Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy
This is a single-arm, open-label, phase II clinical trial. The goal of this study is to evaluate the efficacy and safety of cetuximab plus irinotecan in patients with NeoRAS wild-type primary left-sided mCRC in third-line therapy.
- Trial name
- NCT05962502
- Testing
- Cetuximab and irinotecan
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Sun Yat-sen University
Metastatic Colorectal Cancer (mCRC)
Fruquintinib in Patients With Metastatic Colorectal Cancer
FRUQUENT is an observational study in Germany. The goal of the study is to evaluate how well Fruquintinib works to treat patients with metastatic colorectal cancer that have previously been treated with available standard…
- Trial name
- FRUQUENT (NCT06787105)
- Where
- 42 sites in Germany
- Volunteers
- 150 people
- Sponsor
- iOMEDICO AG
Vitamin D3
XELOX/mFOLFOX Plus Vitamin D3 vs. XELOX/mFOLFOX as Firstline Chemotherapy in mCRC
The study is a randomized,multicenter, double-blinded,phase III study. To explore the affection of vitamin D3 in combination with oxaliplatin plus fluoropyrimidine versus oxaliplatin plus fluoropyrimidine as first-line…
- Trial name
- NCT03389659
- Testing
- vitamin D3
- Volunteers
- 750 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Pancreatic Ductal Adenocarcinoma (mPDAC), Metastatic Colorectal Carcinoma (mCRC)
OSCAR II STUDY - The ONCObind CTC Removal Study
This study is a Prospective Single Arm, dual cohort Open Label Feasibility trial to evaluate the initial safety and signal of efficacy of a novel extracorporeal blood purification (EBP) procedure in either mPDAC or mCRC…
- Trial name
- NCT06655142
- Testing
- ONCObind (Onco-Seraph) 100 Filter, Matched Controls
- Volunteers
- 120 people
- Sponsor
- ExThera Medical Corporation
Metastatic Colorectal Cancer (mCRC)
A Study of Overall Survival in Participants With Metastatic Colorectal Cancer (mCRC)
The purpose of this study is to estimate the overall survival (OS) for US participants diagnosed with metastatic colorectal cancer (mCRC) by using Flatiron Health's individual patient level data.
- Trial name
- NCT05420909
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Bristol-Myers Squibb